About Supernus Pharmaceuticals
Focused entirely on central nervous system disorders, Supernus Pharmaceuticals has built a specialised portfolio of treatments spanning epilepsy, ADHD, and Parkinson's disease since its founding in 2005. Headquartered in Rockville, Maryland, the company operates as a publicly traded, commercial-stage pharmaceutical business listed on Nasdaq under the ticker SUPN.
Supernus concentrates its research and commercialisation efforts on CNS conditions that carry significant unmet medical need, bringing approved therapies to neurologists, psychiatrists, and specialist prescribers across the United States. Its approved product range has included treatments for focal-onset seizures and absence seizures, as well as extended-release formulations that improve patient adherence in complex chronic conditions.
The company expanded its CNS reach through the acquisition of Adamas Pharmaceuticals in 2022, adding a Parkinson's disease treatment to its commercial portfolio and broadening its presence in the movement-disorder segment. This acquisition demonstrated Supernus's strategy of growing through both internal pipeline development and targeted in-licensing or acquisition of late-stage or approved assets within its therapeutic focus area.
Supernus maintains an active pipeline of investigational compounds addressing neurological and psychiatric conditions, reflecting a consistent commitment to expanding its CNS franchise over time. The organisation's commercial infrastructure is built around specialist sales teams and payer access capabilities suited to the neurology and psychiatry markets.
Further information is available at supernus.com.
